P&G's Best Day Since the Toilet-Paper Panic: Thorne Led the Guidance Raise, but the Core Business Is the Real Story
Procter & Gamble's newly acquired supplements brand Thorne drove a higher sales forecast. The more useful signal for investors is that shoppers are still paying up across P&G's everyday brands.
The boring stock had an exciting day
Procter & Gamble sells Pampers, Charmin, Crest and Swiffer, the stuff people buy no matter what the economy is doing. Big jumps aren't really its thing. So this one stood out: as The Daily Upside put it, P&G stock had "its biggest single-day spike since people started hoarding toilet paper in March 2020."
Thorne got the headline. It's a vitamin and supplements brand P&G finished buying for $3.8 billion on Oct. 1, and it led the company to raise its sales forecast. But if you own P&G, or are thinking about it, Thorne isn't the most important thing in this report. The more useful news is that the core business held up, and it did that mostly by charging more.
P&G stock had its biggest single-day spike since people started hoarding toilet paper in March 2020.
What P&G actually said
There were three things worth knowing. First, P&G raised its full-year net sales guidance (its own forecast for revenue growth) from 1%–3% to 2%–4%, with Thorne leading the raise. Second, net sales grew in all five of P&G's business segments from a year earlier. That's a real change. In the fiscal year that ended June 30, executives said shoppers were scrimping on household items, and P&G grew volume (the number of units sold) in only one quarter. Third, growth in healthcare and grooming came from higher prices and from shoppers trading up to pricier products.
The point to underline is that Thorne brings its own sales with it. Its 2025 revenue topped $500 million, and from Oct. 1 on, that counts as P&G's. Some of the higher forecast comes from owning a new business, not from Tide flying off shelves. So whenever a company says it "raised guidance," ask whether the growth was bought or earned. Here it's partly bought, and that's the part of the raise to discount.
Why it matters: shoppers are still paying up
The big worry for a stock like P&G is that stretched consumers stop paying more. Prices are rising fast. Gasoline jumped 9.1% in a month and accounted for more than half of September's 0.6% rise in overall prices. P&G's answer is premiumization, which just means selling fancier, pricier versions of everyday items. You can buy a $1 manual toothbrush or a $400 Oral-B iO Series 10 with an AI coach that points out how badly you brush. There's also a $205 SK-II serum and a $460 Braun razor that analyzes your beard density.
This isn't only a P&G story. Spotify just added more Premium subscribers than it had forecast, even as people swap beef for chicken and skip doctor's appointments. Consumers are cutting back somewhere, but they keep paying for the things they've decided are worth it. P&G is betting a better toothbrush or razor makes that list.
The catch is that price-driven growth has a ceiling. You can only raise prices and upsell for so long if you're not also selling more units. For investors, the number to track over the next few quarters is volume. Sales growth in every segment is encouraging, but it doesn't tell you P&G is moving more product, and that's what would make this growth durable.
Thorne: a real pivot or a pricey side bet?
Thorne gives P&G a different kind of customer. P&G already owns supplement brands, but as The Daily Upside noted, Metamucil "isn't exactly appealing to the same demo." Thorne says most of its revenue comes from shoppers under 40. It sells everything from basic multivitamins to trendy ingredients like berberine, and it teamed up with country singer Megan Moroney on a $22 creatine smoothie sold at the upscale LA grocer Erewhon. P&G is paying for a way into younger, wellness-minded wallets.
That market is big and growing. The Global Wellness Institute expects the wellness economy to grow from $6.8 trillion in 2024 to $9.8 trillion by 2029. Vitamins and supplements made up $167 billion of 2024's total, after growing about 5% a year for five years. CEO Colin Watts told CNBC that Thorne could reach $1 billion in revenue over the next few years.
Keep the scale in mind, though. Thorne is a sliver of that market, and P&G paid up to about 7.6 times Thorne's 2025 revenue. That's a rich price for a business that small, and it only pays off if Thorne grows fast. Unilever is doing the same thing: it closed a reported $1.2 billion deal for gummy maker Grüns on June 1. When two staples giants pay up for wellness brands, it tells you their core aisles aren't growing fast enough on their own. For P&G holders, Thorne is a growth option, not a new engine yet. The scorecard is simple: does Thorne actually approach that $1 billion target, and do P&G's core volumes start climbing alongside the price increases?
Questions
We can't say for sure what moved the stock. Thorne led the guidance raise, but the same report also showed net sales rising in all five segments after a year of weak volumes.
- Procter & Gamble Rosy with Thorne — The Daily Upside
- Spotify Surges on Premium Subscriber Success — The Daily Upside
- Blackstone’s Burgeoning AI Business and Inflows Spark a Rally — The Daily Upside
Editor’s pass: Title: dropped the claim that the stock move was 'less about vitamins.' The sources don't say why investors bought, so the new title makes an editorial call (the core business is the real story) instead of a causal one. I also softened the FAQ answer on what caused the jump. Claims cut or softened: 'P&G doesn't usually move markets' and 'meme-stock kind of day' (unsupported hype); 'Thorne arrived right as P&G's new quarter began' and 'raises the number almost automatically' (fiscal-quarter timing isn't in the sources); the fear that shoppers would 'switch to store brands' (not in sources); 'what it calls premiumization' (P&G isn't quoted using the term); 'a customer it has struggled to reach' (unsupported); the claim that Thorne was bought at a 'growth-stock price' and the explanation of why the stock jumped (speculative). The 7.6x multiple now reads 'up to about 7.6 times' because revenue 'topped' $500M. Removed the meta line about what the sources don't cover, plus the 'has yet to be measured' hedge. Voice: glossed 'guidance' and 'volume,' tightened sentences, cut filler. 'So what' rewrites: the 'What P&G actually said' section now ends with what to discount in the raise. The pricing section ends with the specific metric to track (volume) and why it matters. The Thorne section ends with a concrete two-part scorecard instead of a vague closer. Takeaways now specify that price-driven growth applied to healthcare and grooming, matching the source.
Written + edited by the claude-code:opus agent · grounded in the sources above.